MARKET RESEARCH BRIEFING | FORECAST 2026 –2035
Digital Diabetes Management Market Connected monitoring, smart insulin delivery and AI software converge into a USD 66.86 Bn absolute opportunity through 2035. For investors, strategy teams & B2B decision-makers
2025 market size
2026 estimate
2035 forecast
CAGR 2026–2035
USD 22.82 Bn
USD 26.27 Bn
USD 93.13 Bn
15.1%
Base year
Forecast start
~3.5× the 2026 base
Double-digit growth
Executive summary
Market size trajectory (USD Bn)
• CGMs have moved from a niche Type 1 tool
93.13
into a broad consumer and prevention
+USD 66.86 Bn 2026→2035
product. • Software & Data (19.0% CAGR) outpaces
26.27
22.82
hardware as payers demand integrated, data-driven programs.
2025
2026
• Type 2 diabetes leads end users: USD 9.59
2035
Bn (2025) → USD 38.17 Bn (2035).
Market share leaders (2025) North America — revenue share ~44%
Connected Glucose Monitoring — product ~46%
INDUSTRY ECOSYSTEM AI R&D
›
Devices
› Manufacturing ›
Copyright © Next Move Strategy Consulting
Data mgmt
›
Distribution
›
Regulation
Source: NMSC Digital Diabetes Management Report · 01
02 | GROWTH DRIVERS & OPPORTUNITIES
Prevalence, OTC access and AI dosing power a 15.1% CAGR Impact on CAGR, 2026–2035 (percentage points) Rising Type 2 diabetes & prediabetes prevalence
+4.4 FDA clearance of over-the-counter CGM
+3.1 Expanding payer reimbursement
+2.5 AI-integrated insulin dosing optimization
+1.9 High out-of-pocket costs in emerging markets
−2.1
Highest-growth segments (CAGR 2026–2035)
20.4%
19.9%
19.7%
19.0%
Wellness & Prevention
Prediabetes
Software Subscription
Software & Data
USD 0.91 → 5.59 Bn
USD 2.05 → 12.11 Bn
Demand drivers
USD 3.19 → 18.63 Bn
Whitespace opportunities
• OTC CGM: Abbott Lingo & Libre Rio (FDA, 2024) open the non-insulin and wellness population. • AI decision support: DexCom Smart Basal
(2025) embeds dosing guidance in CGM. • Smart pens: lower-cost bridge between
USD 3.88 → 21.42 Bn
01 02 03
Payer-funded prediabetes screening
ahead of diagnosis Smart pen + CGM data fusion for multiple-daily-injection patients Employer-sponsored programs expanding the Services segment
injections and pumps. Abbott FY2025 CGM sales exceeded USD 7.5
Bn, with Q4 alone at USD 2.0 Bn. Copyright © Next Move Strategy Consulting
Source: NMSC Digital Diabetes Management Report · 02
02 | REGIONAL OPPORTUNITIES
North America leads on scale; Asia-Pacific leads on growth Growth opportunity map (USD Bn, 2025 → 2035)
higher CAGR lower
North America
Europe
FASTEST GROWING
10.05 → 36.32
5.93 → 23.28
Asia-Pacific
CAGR 13.6% · ~44% share
CAGR 14.6%
Broad CGM reimbursement, OTC access
National health system adoption
4.56 → 23.28
18.0% CAGR 2026–2035
Latin America
Middle East & Africa
Rising Type 2 prevalence
1.37 → 6.52
0.91 → 3.73
and mobile health adoption
CAGR 17.1%
CAGR 15.1%
Private healthcare & digital investment
Government chronic-care initiatives
Fastest-growing countries (CAGR)
Largest country markets (USD Bn) 21.4%
India
in China & India
Country
2025
2035
China
18.9%
U.S.
8.65
31.06
South Korea
17.7%
China
1.55
8.71
Brazil
16.9%
Germany
1.78
6.66
Japan
16.2%
UK
1.66
6.29
Canada
1.40
5.26
India
0.68
4.66
Investor takeaway Asia-Pacific adds ~USD 18.7 Bn by 2035 and matches Europe in size; entry strategies should favor price-sensitive connected meters and app-based coaching, as out-of-pocket costs remain the key restraint (−2.1 pts). Copyright © Next Move Strategy Consulting
Source: NMSC Digital Diabetes Management Report · 03
03 | COMPETITIVE SCENARIO
Integrated hardware–software ecosystems hold the structural edge Competitive positioning matrix
Software & services integration →
Service-led platforms
Basis of competition Device accuracy CGM & patch-pump precision
Ecosystem leaders Abbott Medtronic
Teladoc Omada
Software integration Patient apps & clinician platforms Reimbursement depth Payer coverage breadth
DexCom Insulet Market structure
Device specialists
Moderately consolidated — top 10 hold majority share
Hardware depth (CGM, pumps, accuracy) →
Key strategic moves (partnerships & regulatory milestones over large M&A) Jan 2024 · Partnership
2024 · Launch
2025 · Innovation
2025 · Expansion
Abbott CGM integrated
FDA clears Abbott Lingo
DexCom Smart Basal AI
Quebec RAMQ extends
with Insulet Omnipod
& Libre Rio for OTC use
dosing optimizer cleared
Dexcom coverage to
Horizon AID
Type 2
Key companies profiled (selected of 20) Abbott
DexCom
Medtronic
Insulet
Tandem
Roche
Ypsomed
Sinocare
Teladoc
Omada
Senseonics
Glooko
Virta Health
LifeScan
Diabeloop
Copyright © Next Move Strategy Consulting
Positioning qualitative, per NMSC archetypes · 04
04 | LET'S CONNECT
Thank You Connect with our analysts for in-depth insights, segment-level data and strategic guidance on the Digital Diabetes Management market.
Contact us Official website
Phone
www.nextmsc.com
+1 857 758 5017
info@nextmsc.com
Click here for the complete report → nextmsc.com/report/digital-diabetes-management-market-hc5415 Market share of top 10 companies · 20 company profiles · 38 countries
Follow us LinkedIn
YouTube
Copyright © Next Move Strategy Consulting
Twitter / X
YouTube
05